Published in Urologe A on November 01, 1998
[Genetics of testicular germ cell tumors]. Pathologe (2014) 0.75
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Organ sparing surgery for malignant germ cell tumor of the testis. J Urol (2001) 1.99
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
[Prostate cancer centres / prostate centres--certified by DKG or DVPZ]. Aktuelle Urol (2009) 1.39
Inter-reader agreement of the ESUR score for prostate MRI using in-bore MRI-guided biopsies as the reference standard. Eur Radiol (2013) 1.30
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20
Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol (2002) 1.11
Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer (2001) 1.02
[Minimally invasive percutaneous nephrolitholapaxy (MIP)]. Urologe A (2008) 0.98
Eukaryotic initiation factor 3 p110 mRNA is overexpressed in testicular seminomas. Am J Pathol (2000) 0.96
Surgery for metachronous solitary liver metastases of renal cell carcinoma. J Urol (1997) 0.95
[PREFERE - the German prostatic cancer study: questions and claims surrounding study initiation in January 2013]. Urologe A (2013) 0.95
Long-term gonadal toxicity after therapy for Hodgkin's and non-Hodgkin's lymphoma. Ann Hematol (1994) 0.93
Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol (1998) 0.90
Effects of various phosphodiesterase-inhibitors, forskolin, and sodium nitroprusside on porcine detrusor smooth muscle tonic responses to muscarinergic stimulation and cyclic nucleotide levels in vitro. Neurourol Urodyn (1996) 0.89
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99). Int J Clin Pract (2006) 0.89
Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group. Br J Cancer (2002) 0.88
Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br J Cancer (2001) 0.88
Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. I. Identification and characterization. Urol Res (1996) 0.88
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther (2001) 0.88
[Familial synostosis of metacarpi IV and V]. Z Orthop Ihre Grenzgeb (1965) 0.87
Single agent carboplatin for CS IIA/B testicular seminoma. A phase II study of the German Testicular Cancer Study Group (GTCSG). Ann Oncol (2005) 0.86
Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest New Drugs (2005) 0.86
Evaluation of a structured report of functional prostate magnetic resonance imaging in patients with suspicion for prostate cancer or under active surveillance. Urol Int (2012) 0.85
Gene expression profiling in seminoma and nonseminoma. J Clin Oncol (2005) 0.85
Expression of Ksp-cadherin during kidney development and in renal cell carcinoma. Br J Cancer (2005) 0.85
Inter-reader agreement of multi-parametric MR imaging for the detection of prostate cancer: evaluation of a scoring system. Rofo (2012) 0.84
Management of complete ureteral replacement. Experiences and review of the literature. Scand J Urol Nephrol (1997) 0.83
Loss of heterozygosity, differentiation, and clonality in microdissected male germ cell tumours. J Pathol (1999) 0.83
Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer. Anticancer Drugs (2000) 0.82
Pretreatment follicle-stimulating hormone: a prognostic serum marker of spermatogenesis status in patients treated for germ cell cancer. J Urol (1998) 0.81
Synthesis, testing, and characterization of a novel Nafion membrane with superior performance in photoassisted immobilized Fenton catalysis. Langmuir (2004) 0.81
The history of endocrine therapy of benign and malignant diseases of the prostate. World J Urol (2000) 0.81
Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levels. J Cancer Res Clin Oncol (2005) 0.80
Followup results of a combination of calcitonin gene-related peptide and prostaglandin E1 in the treatment of erectile dysfunction. J Urol (1993) 0.80
Success of intracytoplasmic sperm injection in couples with male and/or female chromosome aberrations. Hum Reprod (1997) 0.80
[Certified prostate cancer centers of the German Cancer Society : Current status 2 years after certification and future developments]. Urologe A (2010) 0.79
Long term results and morbidity of paraaortic compared with paraaortic and iliac adjuvant radiation in clinical stage I seminoma. Anticancer Res (2001) 0.79
Transcriptional profiling of transurethral resection samples provides insight into molecular mechanisms of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis (2007) 0.79
[Ablatio testis and enucleation resection]. Aktuelle Urol (2009) 0.79
Holmium laser ablation of the prostate (HoLAP): intermediate-term results of 144 patients. World J Urol (2012) 0.79
[Complete resection of urothelial cancer metastases with curative intent]. Urologe A (2009) 0.79
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells. Urology (2003) 0.79
[Standardised scoring of a multi-parametric 3-T MRI for a targeted MRI-guided prostate biopsy]. Urologe A (2012) 0.78
Human and mouse RAD17 genes: identification, localization, genomic structure and histological expression pattern in normal testis and seminoma. Hum Genet (1999) 0.77
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany]. Urologe A (2003) 0.77
[The modified ureterosigmoidostomy (Mainz pouch II) as a continent form of urinary diversion]. Urologe A (2004) 0.77
[Seminal vesicle sparing radical perineal prostatectomy]. Urologe A (2009) 0.77
Risk factors for relapse in stage I non-seminomatous germ-cell tumors: preliminary results of the German Multicenter Trial. German Testicular Cancer Study Group. Int J Cancer (1999) 0.77
Secondary leukemia after first-line high-dose chemotherapy for patients with advanced germ cell cancer. J Cancer Res Clin Oncol (2004) 0.76
Is there a significance of histamine in the control of the human male sexual response? Andrologia (2011) 0.76
Metastatic leydig-cell tumors of the testis - report of 4 cases and review of the literature. Int J Oncol (1993) 0.76
Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. World J Urol (2001) 0.76
p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder--a helpful parameter in guiding the decision for or against cystectomy? Eur J Cancer (2000) 0.76
Advances in our understanding of the biology, new diagnostic approaches and recent treatment strategies for testicular germ cell cancer. World J Urol (2004) 0.76
Denovo urothelial carcinoma of the upper and lower urinary tract in kidney--transplant patients with end-stage analgesic nephropathy. World J Urol (1995) 0.76
Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment. J Clin Oncol (1998) 0.76
Intracavernous calcitonin gene-related peptide plus prostaglandin E1: possible alternative to penile implants in selected patients. Eur Urol (1994) 0.76
[Chemotherapy for urothelial cancer of the bladder--update 2012]. Aktuelle Urol (2012) 0.76
[Testicular loss due to hemorrhagic infarct in Tauber antegrade scrotal varicocele sclerotherapy]. Urologe A (1997) 0.75
A simple method of blood exchange in mice and its application to immunology. Immunology (1971) 0.75
Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res (1997) 0.75
Familial occurrence of Leydig cell tumors: a report of a case in a father and his adult son. J Urol (1993) 0.75
[Update on first-line and relapse chemotherapy for testicular cancer]. Urologe A (2013) 0.75
Prostate-specific antigen density--a reliable parameter for the detection of prostate cancer? World J Urol (1996) 0.75
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma]. Aktuelle Urol (2012) 0.75
[Metastasized prostate cancer. Position paper on the use of chemotherapy]. Urologe A (2015) 0.75
[Impact of tumor size on long-term survival of patients with organ-confined renal cell cancer]. Aktuelle Urol (2003) 0.75
[Quality control in the implementation of new surgical procedures: Da Vinci robot-assisted systems]. Urologe A (2011) 0.75
[Renal cell carcinoma--any new developments?]. Urologe A (1999) 0.75
Urodynamics and transurethral microwave thermotherapy. World J Urol (1998) 0.75
[Interdisciplinary consensus on diagnosis and therapy of testicular tumors. Results of an update conference based on evidence-based medicine. German Testicular Cancer study Group (GTCSG)]. Strahlenther Onkol (2000) 0.75
[Vessels of the gallbladder in postmortem angiography]. Fortschr Geb Rontgenstr Nuklearmed (1965) 0.75
[Advantages of nerve-sparing pelvic surgery. Animal experiments and clinical results]. Urologe A (2004) 0.75
[New aspects on the identification of genetic alterations and prognostically important biological parameters in renal cell cancer]. Urologe A (1999) 0.75
[Spectrophotometric demonstration of substances on acetate film in the infrared region]. J Chromatogr (1967) 0.75
Late relapse of testicular cancer presenting as differentiated teratoma - report of a case and discussion of the clinical implications. Oncol Rep (1995) 0.75
[Metastatic castration-resistant prostate cancer: position paper for structured therapy monitoring]. Urologe A (2014) 0.75
[Follow-up of urological tumor treatment]. Urologe A (2015) 0.75
Heterogeneous p27(Kip1) expression within primary renal cell cancers, their invasive margins and peritumoral renal parenchyma correlation with pathological and prognostic features. Urol Int (2007) 0.75
[Robot-assisted radical cystectomy: do we actually need a robot?]. Urologe A (2012) 0.75
Analysis of the cyclin-dependent kinase inhibitor p27Kip1 in muscle invasive bladder cancer. Oncol Rep (1999) 0.75
[Systemic therapy of malignant adrenal tumors]. Urologe A (2006) 0.75
[Stool behaviour and local pain after radical perineal and retroperitoneal prostatectomy]. Aktuelle Urol (2011) 0.75
No growth-stimulation of heterotransplanted human testicular cancer cell-lines by recombinant human granulocyte-macrophage colony-stimulating factor (gm-csf). Int J Oncol (1993) 0.75
[Constituent substances in tubercle bacilli]. Z Immunitatsforsch Allerg Klin Immunol (1967) 0.75
Renal-cell carcinoma with intracaval neoplastic extension: stratification and surgical technique. World J Urol (1995) 0.75
Laparoscopic retroperitoneal lymphadenectomy in the management of low-stage testicular cancer: technique and results. Minim Invasive Ther Allied Technol (2005) 0.75
[Thermotherapy of benign prostatic hyperplasia]. Urologe A (1995) 0.75
[Radiofrequency ablation of renal cell carcinomas using MR imaging: initial results]. Rofo (2005) 0.75
[The importance of pathology in the German prostate cancer study PREFERE]. Pathologe (2013) 0.75
[Inguinal lymphadenectomy in penis carcinoma]. Aktuelle Urol (2009) 0.75
[Secondary malignancies in urinary diversions]. Urologe A (2012) 0.75
[Management of complications after residual tumor resection for metastatic testicular cancer]. Urologe A (2014) 0.75
[The interdisciplinary approach to improve treatment quality of prostate cancer. Optimized nerve sparing in radical prostatectomy]. Urologe A (2007) 0.75
[On diagnosis of the arterial collateral circulation of the kidney]. Fortschr Geb Rontgenstr Nuklearmed (1966) 0.75